MX2011009955A - Atropisomeros de derivados de 2-purinil-3-tolil-quinazolinona y metodos de uso. - Google Patents
Atropisomeros de derivados de 2-purinil-3-tolil-quinazolinona y metodos de uso.Info
- Publication number
- MX2011009955A MX2011009955A MX2011009955A MX2011009955A MX2011009955A MX 2011009955 A MX2011009955 A MX 2011009955A MX 2011009955 A MX2011009955 A MX 2011009955A MX 2011009955 A MX2011009955 A MX 2011009955A MX 2011009955 A MX2011009955 A MX 2011009955A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- atropisomers
- purinyl
- tolyl
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Abstract
La invención proporciona compuestos, composiciones y métodos para tratar ciertas condiciones inflamatorias y/u oncología administrando un compuesto que inhibe isoformas PD K, particularmente la isoforma delta. Adicionalmente proporciona estereoisómeros específicos de un compuesto útil para estos métodos. En términos particulares, el compuesto es un atropisómero ópticamente activo de 2-((6-amino-9H-purin-9-il)metil )-5-metil-3-o-tolilquinazolin-4(3H)-ona.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16298009P | 2009-03-24 | 2009-03-24 | |
US23155009P | 2009-08-05 | 2009-08-05 | |
PCT/US2010/028554 WO2010111432A1 (en) | 2009-03-24 | 2010-03-24 | Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011009955A true MX2011009955A (es) | 2011-11-18 |
Family
ID=42289320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011009955A MX2011009955A (es) | 2009-03-24 | 2010-03-24 | Atropisomeros de derivados de 2-purinil-3-tolil-quinazolinona y metodos de uso. |
Country Status (19)
Country | Link |
---|---|
US (1) | US8440677B2 (es) |
EP (1) | EP2411391A1 (es) |
JP (1) | JP2012521994A (es) |
KR (1) | KR20120002995A (es) |
CN (1) | CN102439012A (es) |
AP (1) | AP2011005943A0 (es) |
AU (1) | AU2010229968A1 (es) |
BR (1) | BRPI1012333A2 (es) |
CA (1) | CA2756347A1 (es) |
CL (1) | CL2011002359A1 (es) |
CO (1) | CO6450655A2 (es) |
EA (1) | EA019499B1 (es) |
EC (1) | ECSP11011412A (es) |
IL (1) | IL215251A0 (es) |
MX (1) | MX2011009955A (es) |
NZ (1) | NZ595307A (es) |
PE (1) | PE20120602A1 (es) |
SG (1) | SG174529A1 (es) |
WO (1) | WO2010111432A1 (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
WO2005016348A1 (en) * | 2003-08-14 | 2005-02-24 | Icos Corporation | Method of inhibiting immune responses stimulated by an endogenous factor |
ES2605792T3 (es) | 2004-05-13 | 2017-03-16 | Icos Corporation | Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana |
US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
NZ592880A (en) | 2008-11-13 | 2013-06-28 | Gilead Calistoga Llc | Combinations of purine derivatives and proteasome inhibitors such as bortezomib for the treatment of hematological malignancy |
CA2756347A1 (en) | 2009-03-24 | 2010-09-30 | Gilead Calistoga Llc | Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use |
WO2010123931A1 (en) * | 2009-04-20 | 2010-10-28 | Calistoga Pharmaceuticals Inc. | Methods of treatment for solid tumors |
JP5718323B2 (ja) * | 2009-05-29 | 2015-05-13 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 放射標識されたpde10阻害剤 |
JP2013500257A (ja) * | 2009-07-21 | 2013-01-07 | ギリアード カリストガ エルエルシー | Pi3kインヒビターでの肝障害の処置 |
GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
EP2518071A1 (en) * | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Imidazopyridine derivatives as PI3K inhibitors |
EP2518070A1 (en) * | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
HUE036052T2 (hu) | 2011-12-15 | 2018-06-28 | Novartis Ag | PI3K aktivitással vagy funkcióval rendelkezõ inhibitorok alkalmazása |
AP2014007875A0 (en) | 2012-03-05 | 2014-08-31 | Gilead Calistoga Llc | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
LT2834244T (lt) | 2012-03-13 | 2016-11-10 | Respivert Limited | Kristalinės pi3 kinazės slopikliai |
KR102216606B1 (ko) | 2012-07-04 | 2021-02-17 | 리젠 파마슈티컬스 소시에떼 아노님 | 선택적 pi3k 델타 억제제 |
WO2014015523A1 (en) * | 2012-07-27 | 2014-01-30 | Hutchison Medipharma Limited | Novel heteroaryl and heterocycle compounds, compositions and methods |
US9388189B2 (en) * | 2012-10-16 | 2016-07-12 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
WO2014060431A1 (en) * | 2012-10-16 | 2014-04-24 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
KR20150079745A (ko) * | 2012-11-08 | 2015-07-08 | 리젠 파마슈티컬스 소시에떼 아노님 | Pde4 억제제 및 pi3 델타 또는 이중 pi3 델타-감마 키나아제 억제제를 함유하는 약제학적 조성물 |
TW201522341A (zh) * | 2013-03-15 | 2015-06-16 | Respivert Ltd | 化合物 |
US9227977B2 (en) | 2013-03-15 | 2016-01-05 | Respivert Ltd. | Phosphoinositide 3-kinase inhibitors |
UY35675A (es) | 2013-07-24 | 2015-02-27 | Novartis Ag | Derivados sustituidos de quinazolin-4-ona |
CN104447727B (zh) * | 2013-09-02 | 2018-04-27 | 广东东阳光药业有限公司 | 取代的氨基嘧啶类化合物及其使用方法和用途 |
MX2016003456A (es) | 2013-09-22 | 2017-05-25 | Calitor Sciences Llc | Compuestos aminopirimidina sustituidos y metodos de uso. |
MX2016008259A (es) | 2013-12-20 | 2016-10-13 | Gilead Calistoga Llc | Metodo de proceso para inhibidores de fosfatidilinositol 3-cinasa. |
US9708327B2 (en) | 2013-12-20 | 2017-07-18 | Gilead Calistoga Llc | Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
EP3148586A1 (en) * | 2014-05-27 | 2017-04-05 | Almirall S.A. | Combination |
CA2949932C (en) | 2014-05-27 | 2021-08-10 | Rhizen Pharmaceuticals Sa | Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations |
MX2016016530A (es) | 2014-06-13 | 2017-03-27 | Gilead Sciences Inc | Inhibidores de fosfatidilinositol 3-quinasa. |
UA115296C2 (uk) | 2014-07-04 | 2017-10-10 | Люпін Лімітед | Хінолізинонові похідні як інгібітори pi3k |
WO2017027883A1 (en) | 2015-08-13 | 2017-02-16 | San Diego State University Research Foundation | Atropisomerism for increased kinase inhibitor selectivity |
RS64678B1 (sr) | 2016-01-11 | 2023-11-30 | Univ London Queen Mary | Inhibitori pi3k p-delta 110 za upotrebu u isporuci virusa u lečenju kancera |
CN109641887B (zh) | 2016-06-22 | 2022-09-20 | 美国政府健康及人类服务部 | 可用作用于治疗癌症的突变idh1抑制剂的噻唑衍生物 |
US10016425B2 (en) | 2016-11-03 | 2018-07-10 | King Saud University | Anti-ulcerative colitis compound |
US20220112217A1 (en) * | 2018-08-21 | 2022-04-14 | Medshine Discovery Inc. | Pyrazolopyrimidine derivative and use thereof as pi3k inhibitor |
BR112022020342A2 (pt) | 2020-04-10 | 2022-12-13 | Gb005 Inc | Inibidores da quinase |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1053063A (es) | 1963-05-18 | |||
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
DE2027645A1 (de) | 1970-06-05 | 1971-12-09 | Byk Gulden Lomberg Chemische Fa bnk GmbH, 7750 Konstanz | Piperazinylalkyl chinazolon (4) den vate, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel |
NL7204972A (es) | 1971-04-21 | 1972-10-24 | ||
US3897432A (en) | 1971-04-21 | 1975-07-29 | Merck & Co Inc | Substituted benzimidazole derivatives |
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
DE2644265C2 (de) | 1976-09-30 | 1983-02-10 | Bayer Ag, 5090 Leverkusen | Chinazoline |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
US4183931A (en) | 1977-09-08 | 1980-01-15 | Research Corporation | 2-Ketoalkyl-4(3H)-quinazolinones |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
DE2812635A1 (de) | 1978-03-22 | 1979-09-27 | Bayer Ag | Heterocyclische verbindungen |
JPS55118918A (en) | 1979-03-06 | 1980-09-12 | Mitsubishi Electric Corp | Production of quinazolone ring-containing epoxy resin |
JPS55118917A (en) | 1979-03-06 | 1980-09-12 | Mitsubishi Electric Corp | Production of quinazolone ring-containing epoxy resin |
US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
JPS6017375B2 (ja) | 1979-06-20 | 1985-05-02 | 三菱電機株式会社 | ポリアミド樹脂の製造方法 |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4925673A (en) | 1986-08-18 | 1990-05-15 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
USRE35862E (en) | 1986-08-18 | 1998-07-28 | Emisphere Technologies, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
US6696250B1 (en) | 1986-12-03 | 2004-02-24 | Competitive Technologies, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
US5124331A (en) | 1988-03-02 | 1992-06-23 | Yoshitomi Pharmaceutical Industries, Ltd. | 3,4-dihydrothieno[2,3-d]pyrimidine compounds and their pharmaceutical use |
US5225347A (en) | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Therapeutic ribozyme compositions and expression vectors |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
FR2675803B1 (fr) | 1991-04-25 | 1996-09-06 | Genset Sa | Oligonucleotides fermes, antisens et sens et leurs applications. |
EP0525960B1 (en) | 1991-06-18 | 1996-03-20 | American Home Products Corporation | Use of rapamycin for the treatment of adult T-cell leukemia/lymphoma |
DE69312700T2 (de) | 1992-04-14 | 1998-02-19 | Cornell Res Foundation Inc | Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung |
US5658780A (en) | 1992-12-07 | 1997-08-19 | Ribozyme Pharmaceuticals, Inc. | Rel a targeted ribozymes |
GB9301000D0 (en) | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
US5378725A (en) | 1993-07-19 | 1995-01-03 | The Arizona Board Of Regents | Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof |
GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
FI951367A (fi) | 1994-03-28 | 1995-09-29 | Japan Energy Corp | Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit) |
US5480906A (en) | 1994-07-01 | 1996-01-02 | Eli Lilly And Company | Stereochemical Wortmannin derivatives |
CA2197205A1 (en) | 1994-08-12 | 1996-02-22 | Reid W. Vonborstel | Methods for treating sepsis or inflammatory diseases with oxypurine nucleosides |
US5561138A (en) | 1994-12-13 | 1996-10-01 | American Home Products Corporation | Method of treating anemia |
JP3233802B2 (ja) | 1994-12-15 | 2001-12-04 | 関西電力株式会社 | 燃焼排ガス中の炭酸ガスと窒素酸化物を除去する方法 |
US6043062A (en) | 1995-02-17 | 2000-03-28 | The Regents Of The University Of California | Constitutively active phosphatidylinositol 3-kinase and uses thereof |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5948664A (en) | 1996-02-29 | 1999-09-07 | The Regents Of The University Of California | PI 3-kinase polypeptides |
CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
ATE242232T1 (de) | 1996-05-15 | 2003-06-15 | Pfizer | 2,3,6-trisubstituierte 4(3h)-chinazolinone |
GB9611460D0 (en) | 1996-06-01 | 1996-08-07 | Ludwig Inst Cancer Res | Novel lipid kinase |
US5858753A (en) | 1996-11-25 | 1999-01-12 | Icos Corporation | Lipid kinase |
RU2200161C2 (ru) | 1996-12-31 | 2003-03-10 | Др. Редди'З Рисерч Фаундейшн | Новые производные азолидиндиона, способ их получения (варианты), фармацевтические композиции на их основе, способ предупреждения или лечения, способ снижения глюкозы и промежуточное соединение |
GB9702701D0 (en) | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
IL130897A0 (en) | 1997-02-28 | 2001-01-28 | Pfizer Prod Inc | Atropisomers of 3-heteroaryl-4 (3H)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions |
AU744028B2 (en) | 1997-02-28 | 2002-02-14 | Pfizer Products Inc. | Atropisomers of 3-aryl-4(3H)-quinazolinones and their use as ampa-receptor antagonists |
EP0884310B1 (en) | 1997-06-09 | 2005-09-07 | Pfizer Products Inc. | Quinazolin-4-one ampa antagonists |
WO1999001139A1 (en) | 1997-07-03 | 1999-01-14 | Thomas Jefferson University | An improved method for design and selection of efficacious antisense oligonucleotides |
IL125950A0 (en) | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
JP2002500188A (ja) | 1998-01-08 | 2002-01-08 | ザ・ユニバーシティ・オブ・バージニア・パテント・ファウンデーション | A2aアデノシンレセプター作動因子 |
ATE286032T1 (de) | 1998-04-23 | 2005-01-15 | Reddys Lab Ltd Dr | Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen |
US6048970A (en) | 1998-05-22 | 2000-04-11 | Incyte Pharmaceuticals, Inc. | Prostate growth-associated membrane proteins |
US6100090A (en) | 1999-06-25 | 2000-08-08 | Isis Pharmaceuticals Inc. | Antisense inhibition of PI3K p85 expression |
US6046049A (en) | 1999-07-19 | 2000-04-04 | Isis Pharmaceuticals Inc. | Antisense modulation of PI3 kinase p110 delta expression |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
EP1939203B1 (en) | 2000-04-25 | 2014-11-19 | ICOS Corporation | Inhibitors of human phosphatidyl-inositol 3-kinase delta isoform |
SI2223922T1 (sl) | 2000-04-25 | 2016-04-29 | Icos Corporation | Inhibitorji humane fosfatidil-inositol 3-kinazne delta izoforme |
US20040092561A1 (en) | 2002-11-07 | 2004-05-13 | Thomas Ruckle | Azolidinone-vinyl fused -benzene derivatives |
BR0312650A (pt) | 2002-07-10 | 2005-05-03 | Applied Research Systems | Derivados de benzeno fundido azolidinona-vinila |
GB0217777D0 (en) | 2002-07-31 | 2002-09-11 | Novartis Ag | Organic compounds |
US20040023390A1 (en) | 2002-08-05 | 2004-02-05 | Davidson Beverly L. | SiRNA-mediated gene silencing with viral vectors |
CA2400254A1 (en) | 2002-09-19 | 2004-03-19 | University Health Network | Compositions and methods for treating heart disease |
DE60324296D1 (de) | 2002-09-30 | 2008-12-04 | Bayer Healthcare Ag | Kondensierte azolpyrimidinderivate |
EP1569653A1 (en) | 2002-12-06 | 2005-09-07 | Warner-Lambert Company LLC | Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k |
WO2004056820A1 (en) | 2002-12-20 | 2004-07-08 | Warner-Lambert Company Llc | Benzoxazines and derivatives thereof as inhibitors of pi3ks |
EA012240B1 (ru) | 2003-04-03 | 2009-08-28 | Семафор Фармасьютикалз, Инк. | Пролекарства ингибиторов киназы pi-3 |
BRPI0410913A (pt) | 2003-06-05 | 2006-06-27 | Warner Lambert Co | benzotiofenos substituìdos com cicloalquil e heterocicloalquil como agentes terapêuticos |
JP2006526605A (ja) | 2003-06-05 | 2006-11-24 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | 治療剤としての3−置換インドール類及びそれらの誘導体 |
JP2006526614A (ja) | 2003-06-05 | 2006-11-24 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | 治療用剤としての3−アリールスルファニル及び3−ヘテロアリールスルファニル置換ベンゾ[b]チオフェン |
JP2006526610A (ja) | 2003-06-05 | 2006-11-24 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | 療法薬としてのシクロアルキルスルファニル置換ベンゾ[b]チオフェン |
EP1644364A1 (en) | 2003-06-05 | 2006-04-12 | Warner-Lambert Company LLC | Tetrazol benzofurancarboxamides with pi3k activity as therapeutic agents |
US20040259926A1 (en) | 2003-06-05 | 2004-12-23 | Bruendl Michelle M. | 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents |
US20050054614A1 (en) | 2003-08-14 | 2005-03-10 | Diacovo Thomas G. | Methods of inhibiting leukocyte accumulation |
WO2005016348A1 (en) | 2003-08-14 | 2005-02-24 | Icos Corporation | Method of inhibiting immune responses stimulated by an endogenous factor |
US20050239809A1 (en) * | 2004-01-08 | 2005-10-27 | Watts Stephanie W | Methods for treating and preventing hypertension and hypertension-related disorders |
ES2605792T3 (es) * | 2004-05-13 | 2017-03-16 | Icos Corporation | Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana |
CA2566436C (en) | 2004-05-13 | 2011-05-10 | Vanderbilt University | Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis |
JP2008500338A (ja) * | 2004-05-25 | 2008-01-10 | イコス・コーポレイション | 造血細胞の異常増殖を治療及び/又は予防する方法 |
CA2569406A1 (en) * | 2004-06-04 | 2005-12-22 | Icos Corporation | Methods for treating mast cell disorders |
EP1885356A2 (en) | 2005-02-17 | 2008-02-13 | Icos Corporation | Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation |
TW200811185A (en) | 2005-12-22 | 2008-03-01 | Prolexys Pharmaceuticals Inc | Fused pyrimidones and thiopyrimidones, and uses thereof |
EP2097422A4 (en) | 2006-11-13 | 2010-04-14 | Lilly Co Eli | THIENOPYRIMIDINONE FOR THE TREATMENT OF INFLAMMATORY DISEASES AND CARCINOMAS |
US20110160232A1 (en) | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
US20090131512A1 (en) | 2007-10-31 | 2009-05-21 | Dynavax Technologies Corp. | Inhibition of type I in IFN production |
KR101653842B1 (ko) | 2008-01-04 | 2016-09-02 | 인텔리카인, 엘엘씨 | 특정 화학 물질, 조성물 및 방법 |
NZ592880A (en) | 2008-11-13 | 2013-06-28 | Gilead Calistoga Llc | Combinations of purine derivatives and proteasome inhibitors such as bortezomib for the treatment of hematological malignancy |
CA2745280A1 (en) | 2008-12-04 | 2010-06-10 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders |
CA2756347A1 (en) | 2009-03-24 | 2010-09-30 | Gilead Calistoga Llc | Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use |
WO2010123931A1 (en) | 2009-04-20 | 2010-10-28 | Calistoga Pharmaceuticals Inc. | Methods of treatment for solid tumors |
JP2013500257A (ja) * | 2009-07-21 | 2013-01-07 | ギリアード カリストガ エルエルシー | Pi3kインヒビターでの肝障害の処置 |
CA3007787C (en) | 2010-06-03 | 2020-03-10 | Pharmacyclics Llc | The use of inhibitors of bruton's tyrosine kinase (btk) |
-
2010
- 2010-03-24 CA CA2756347A patent/CA2756347A1/en not_active Abandoned
- 2010-03-24 SG SG2011068822A patent/SG174529A1/en unknown
- 2010-03-24 EP EP10722454A patent/EP2411391A1/en not_active Withdrawn
- 2010-03-24 US US12/731,089 patent/US8440677B2/en not_active Expired - Fee Related
- 2010-03-24 NZ NZ595307A patent/NZ595307A/xx not_active IP Right Cessation
- 2010-03-24 AP AP2011005943A patent/AP2011005943A0/xx unknown
- 2010-03-24 WO PCT/US2010/028554 patent/WO2010111432A1/en active Application Filing
- 2010-03-24 AU AU2010229968A patent/AU2010229968A1/en not_active Abandoned
- 2010-03-24 JP JP2012502219A patent/JP2012521994A/ja active Pending
- 2010-03-24 CN CN2010800226099A patent/CN102439012A/zh active Pending
- 2010-03-24 BR BRPI1012333A patent/BRPI1012333A2/pt not_active IP Right Cessation
- 2010-03-24 MX MX2011009955A patent/MX2011009955A/es active IP Right Grant
- 2010-03-24 EA EA201171160A patent/EA019499B1/ru not_active IP Right Cessation
- 2010-03-24 PE PE2011001710A patent/PE20120602A1/es not_active Application Discontinuation
- 2010-03-24 KR KR1020117024913A patent/KR20120002995A/ko not_active Application Discontinuation
-
2011
- 2011-09-20 IL IL215251A patent/IL215251A0/en unknown
- 2011-09-23 CL CL2011002359A patent/CL2011002359A1/es unknown
- 2011-10-20 CO CO11140750A patent/CO6450655A2/es not_active Application Discontinuation
- 2011-10-21 EC ECSP11011412 patent/ECSP11011412A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP2411391A1 (en) | 2012-02-01 |
SG174529A1 (en) | 2011-10-28 |
NZ595307A (en) | 2013-11-29 |
AU2010229968A1 (en) | 2011-10-13 |
US8440677B2 (en) | 2013-05-14 |
ECSP11011412A (es) | 2012-03-30 |
PE20120602A1 (es) | 2012-05-21 |
WO2010111432A1 (en) | 2010-09-30 |
AP2011005943A0 (en) | 2011-10-31 |
EA019499B1 (ru) | 2014-04-30 |
CA2756347A1 (en) | 2010-09-30 |
BRPI1012333A2 (pt) | 2016-03-29 |
US20100249155A1 (en) | 2010-09-30 |
EA201171160A1 (ru) | 2012-04-30 |
CO6450655A2 (es) | 2012-05-31 |
JP2012521994A (ja) | 2012-09-20 |
CN102439012A (zh) | 2012-05-02 |
CL2011002359A1 (es) | 2012-04-09 |
KR20120002995A (ko) | 2012-01-09 |
IL215251A0 (en) | 2011-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2011009955A (es) | Atropisomeros de derivados de 2-purinil-3-tolil-quinazolinona y metodos de uso. | |
MX2012000817A (es) | Tratamiento para desordenes del higado con inhibidores pi3k. | |
MX2012000709A (es) | Inhibidores de pirrolopiridina de cinasas. | |
UA108743C2 (uk) | Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази | |
NZ708864A (en) | Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors | |
JO3025B1 (ar) | الأندازولات المستبدلة بالأوكسازول كمثبطات كيناز pi3 | |
MX350761B (es) | Inhibidores de isoindolinona de fosfatidilinositol 3-cinasa. | |
NZ708870A (en) | Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors | |
GB201104267D0 (en) | Pyrrolopyridineamino derivatives | |
EA201190158A1 (ru) | Производные бензофуранила для применения в качестве ингибиторов глюкокиназы | |
TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
TW200942536A (en) | PIM kinase inhibitors and methods of their use | |
NO20092569L (no) | Inhibitorer av Akt-aktivitet | |
UA105911C2 (uk) | Сульфонамідні похідні | |
MX338489B (es) | Derivados de hidantoina utiles como inhibidores de kv3. | |
MX346336B (es) | Derivados de quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinasa. | |
NO20090434L (no) | Heteroarylforbindelser anvendbare som inhibitorer av E1-aktiverende enzymer | |
MX2011011854A (es) | Dihidropirimidinonas para uso como inhibidores de la bace2. | |
CR11757A (es) | Compuestos de triazina como inhibidores mtor y quinasa pi3 | |
EA201390198A1 (ru) | Гетероциклическое соединение | |
MX2009006706A (es) | Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos. | |
MA32393B1 (fr) | Composés et compositions servant d'inhibiteurs de kinases | |
WO2010135524A8 (en) | Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases | |
UA103616C2 (ru) | Замещенные гамма-лактамы как терапевтические агенты | |
MX2011009033A (es) | Inhibidores triciclicos de cinasa pirazolopiridina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |